Screener
Stoke Therapeutics, Inc. STOK Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211874
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Basic | 63,063,507 | 57,862,674 |
| Diluted | 63,063,507 | 59,398,600 |
| Comprehensive (loss) income: | ||
| Net (loss) income | $(50,003) | $112,879 |
| Other comprehensive (loss) gain: | ||
| Unrealized (loss) gain on marketable securities | (658) | 47 |
| Total other comprehensive (loss) gain | $(658) | $47 |
| Comprehensive (loss) income | $(50,661) | $112,926 |
Item 1. Financial Statements.
FAQ
- What is Stoke Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
- Stoke Therapeutics, Inc. (STOK) reported comprehensive income (loss), net of tax, attributable to parent of -$50.66M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- Stoke Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent decreased by 144.9% year-over-year, from $112.93M to -$50.66M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
- Over 4 years (2021 to 2025), Stoke Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent has grown at a -48.2% compound annual growth rate (CAGR), from -$85.97M to -$6.19M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- This metric represents the total change in equity from non-owner sources, combining net income with other comprehensive income items. It serves as a comprehensive measure of the company's total financial performance and wealth generation during a specific period. Investors use this to assess the overall impact of both operational results and external market factors on shareholder value.
Ask your AI about Stoke Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude